VKTX

VIKING THERAPEUTICS INC

VKTX·92686J106·US·Common Stock·Healthcare - Biotechnology-13D/G

VKTX (VIKING THERAPEUTICS INC) is held by 167 institutional investors as of Q2 2026. Largest holders: FMR LLC ($247.2M), BlackRock, Inc. ($241.5M), STATE STREET CORP ($218.7M). Net institutional sentiment: Mixed.

167
Holders
(13 Elite)
$2.6B
Total Value
59% (165)
Consensus
97 buying - 68 selling
13F: Insider & Congress: Updated regularly
VKTX

Smart Money Verdict

View all
Loading verdict
Held by 167 funds
13 elite

Who's Trading

Source dates: Price Aug 27, 2026 · Insiders Mar 10, 2026 · Activists Apr 30, 2026 · Congress none

ActivistVAVanguard Capital Management5.1%Apr 30, 2026
ActivistThe Vanguard GroupThe Vanguard Group0.0%Mar 27, 2026
InsiderAWAubuchon Neil WilliamBuy $150KMar 10, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
6.3M(+5.2%)$247.2M0.0%-12.38%
32
Decreased
6.2M(-10.0%)$241.5M0.0%-10.22%
0
Increased
5.6M(+27.6%)$218.7M0.0%+6.93%
38
Increased
5.1M(+0.8%)$197.1M0.0%+7.48%
31
Increased
4.5M(+0.5%)$174.9M0.0%+7.57%
30
Decreased
3.9M(-11.2%)$153.6M0.1%+16.47%
0
Increased
3.5M(+15.7%)$136M0.0%-21.15%
35
Increased
2.2M(+28.4%)$84.1M0.0%-12.18%
37
Increased
2.1M(+0.8%)$81.9M0.0%+49.25%
30
Decreased
1.8M(-12.6%)$70.8M0.0%+15.56%
0
Decreased
1.6M(-4.2%)$62.6M0.0%-1.89%
0
Increased
981,700(+81.6%)$38.3M0.0%-5.21%
45
Decreased
951,515(-24.6%)$37.1M0.0%-19.17%
0
Decreased
942,841(-1.9%)$36.8M0.0%+2.02%
0
Decreased
936,055(-30.5%)$36.5M0.0%+15.45%
0
Increased
915,185(+88.4%)$36.4M0.0%-0.66%
45
Increased
899,558(+20.1%)$35.1M0.0%+8.41%
34
Increased
816,367(+15.7%)$31.8M0.0%-10.86%
33
Decreased
794,660(-61.7%)$31M0.0%+3.29%
0
Increased
732,047(+3.0%)$28.6M0.0%+6.97%
30

Showing 1-20 of 177

1 / 9
VKTXVKTXVIKING THERAPEUTICS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used